AustCancer subsidiary signs distribution deal
By Renate Krelle
Tuesday, 06 July, 2004
Tuesday, 06 July, 2004
ACT US, the US subsidiary of oncology specialist Australian Cancer Technology ("AustCancer") (ASX: ACU) has signed a distribution deal for its revisys range of nutritional supplements.
Under the deal, wholesale drug cooperative Rochester Drug Cooperative will stock revisys in more than eight hundred community retail pharmacies long-term care pharmacies and home health care stores in New York State, Pennsylvania and New Jersey.
Related News
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
Newborns have elevated levels of an Alzheimer's biomarker
What do the brains of newborns and patients with Alzheimer's disease have in common? Both...
